Improving the Oral Bioavailability of an Anti-Glioma Prodrug CAT3 Using Novel Solid Lipid Nanoparticles Containing Oleic Acid-CAT3 Conjugates

• Main Authors: Hongliang Wang (Author), Lin Li (Author), Jun Ye (Author), Rubing Wang (Author), Renyun Wang (Author), Jinping Hu (Author), Yanan Wang (Author), Wujun Dong (Author), Xuejun Xia (Author), Yanfang Yang (Author), Yue Gao (Author), Lili Gao (Author), Yuling Liu (Author)
• Format: Book
• Published: MDPI AG, 2020-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

13a-(S)-3-pivaloyloxyl-6,7-dimethoxyphenanthro(9,10-b)-indolizidine (CAT3) is a novel oral anti-glioma pro-drug with a potent anti-tumor effect against temozolomide-resistant glioma in vivo. However, poor lipid solubility has limited the encapsulation efficacy during formulation development. Moreove...